You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201461 - 201470 of 204843 results
  1. Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonists for Peripheral Pain

    SBC: HALIMED PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated effects that have limited their development. Perhaps the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Adolescent Screener and Opioid Assessment for Patients with Pain (A-SOAPP)

    SBC: Inflexxion, Inc.            Topic: NIDA

    DESCRIPTION (provided by applicant): Pain management including the use of opioid analgesics is recommended for adolescents who are suffering from recurrent or chronic pain associated with a specific etiology such as cancer, cystic fibrosis, sickle cell anemia, hemophilia or organ transplants (see citations by etiology in letter of support from CO-I, Dr. Solodiuk). Preventive screening tools provi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Novel selective alpha4beta2 nicotinic receptor antagonists for smoking cessation

    SBC: ASSUAGE PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Smoking remains the number one avoidable cause of death in the United States. Current therapies including nicotine replacement, inhibition of the dopamine system with bupropion, and partial activation of the 4 2 neuronal nicotinic acetylcholine receptor (nAChR) with varenicline have not been particularly effective, with relapse rates at nearly 80% regardless of ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Building an open-source cloud-based computational platform to improve data access

    SBC: BIODATOMICS, LLC            Topic: NIDA

    We propose to develop a novel, cost-effective, cloud-based data and analytics platform that will provide efficient data storage solutions and enhanced analytics, annotation and reporting capabilities for supporting and accelerating clinical and molecular research in the treatment of substance use disorders (SUD). This open source platform, which leverages existing BioDX technology, will provide a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Cannabinergic Receptor Antagonists for Nicotine Addiction

    SBC: MAKSCIENTIFIC            Topic: NIDA

    DESCRIPTION (provided by applicant): Existing evidence in animals and man indicates that blockade of the CB1 receptor may offer an effective approach for combating nicotine addiction. Early studies in humans have documented these effects. This Phase I application proposes studies to design advanced CB1 pyrrolidinone antagonists toward the development of medications for smoking cessation. Our inten ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Quantitative Test of the Success/Reduction of Harm of Smoking Cessation Treatment

    SBC: BEHAVIORAL DIAGNOSTICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Cigarette smoking is the most common preventable cause of morbidity and mortality in the United States. Over the past 20 years, several effective treatments, including varenicline, bupropion and nicotine replacement treatments (NRT, such as nicotine gum or patches) have been developed. Despite significant efforts, the overall success of these treatments for sm ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Using Technology to Improve Clinical Counseling of Adolescent Risky Behaviors

    SBC: POSSIBILITIES FOR CHANGE LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): The goal of this SBIR is to develop an innovative adolescent primary health care delivery model for use in primary care that overcomes barriers of health care provider time, skill and teen engagement when providing effective tobacco use reduction counseling. This will be achieved by creating a web-based counseling module that will provide interactive, technolog ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Innovative Positive Juvenile Justice Tools for Youth Courts

    SBC: National Health Promotion Associates, Inc.            Topic: NIDA

    ABSTRACT Adolescents in underserved, urban communities are disproportionately involved in the juvenile justice system. Youth involvement in the court system is a serious public health concern. In recent years, juvenile justice professionals have begun to supplement traditional efforts aimed at discipline and punishment with an asset- based perspective referred to as positive youth justice (PYJ). ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Long acting injected liposomal buprenorphine for chronic pain/addiction in people

    SBC: Plumb Pharmaceuticals LLC            Topic: NIDA

    DESCRIPTION: In this proposal, Comfort Care for Animals LLC (CCA) (Madison, WI) will create slow-release (minimum 10-12 days in this Phase, with an ultimate goal of 28 days) injectable liposomal buprenorphine formulation to treat moderate to severe post-surgical or chronic pain in people and animals and to use as a treatment for opioid addiction in people. This innovative new drug-delivery system ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Phone app for grounding (de-escalation) of substance-abusing transition-age youth

    SBC: TREATMENT INNOVATIONS, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Substance use disorder (SUD) is the second most common psychiatric diagnosis in the U.S. population, with 14.6% developing it in their lifetime. Transition-age youth (TAY) from ages 18-24 are especially vulnerable to substance use, misuse, and SUD. This developmental period, termed the age of instability includes tasks such as leaving home; entering college; ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government